Amongst users of continuous subcutaneous insulin infusion (CSII) or multiple daily insulin injections (MDI), the main treatment regimens used for older children and adolescents with T1DM, reports indicate no significant difference in glycaemic control with “reasonable risk” of hypoglycaemia and hyperglycaemia (7, 8). This evidence concerns the gene INS and Hypoglycemia.